// App-Quantinova.ai

PB0886 : Prophylaxis with Turoctocog Alfa Pegol (N8-GP) Maintains Improvements in Health-Related Quality of Life (HRQoL) and Treatment Satisfaction (TS) over ≥4.5 Years in Patients with Haemophilia A (HA)

Researchers

Presenter

  • P. Giangrande

Principal Investigators

  • X.Y. Lee

  • N. Curry

  • S. Benchikh El Fegoun

Medical Centers

  • Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, United Kingdom

  • Novo NordiskA/S, Soborg, Denmark

  • Churchill Hospital, Oxford Haemophilia & Thrombosis Centre and Oxford NIHR BRC, Oxford, United Kingdom

  • Novo Nordisk Health Care A/S, Zurich, Switzerland

Locations

  • United Kingdom

  • Denmark

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • NN7008

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved